<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01888484</url>
  </required_header>
  <id_info>
    <org_study_id>SCGAM-01</org_study_id>
    <nct_id>NCT01888484</nct_id>
  </id_info>
  <brief_title>Study of Octanorm Subcutaneous IG in Patients With PID</brief_title>
  <official_title>Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Octapharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label phase III study with a 12-week wash-in/wash-out period followed by a&#xD;
      12-month efficacy period. The main goals of the study are to assess the efficacy of octanorm&#xD;
      in preventing serious bacterial infections (SBI) compared with historical control data and to&#xD;
      evaluate the pharmacokinetic (PK) characteristics of octanorm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">June 9, 2020</completion_date>
  <primary_completion_date type="Actual">June 9, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of SBI Per Person-year</measure>
    <time_frame>Every 4 weeks until the final evaluation at week 65.</time_frame>
    <description>The primary efficacy outcome is the rate of SBI (Serious bacterial infections - defined as bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess) per person-year on treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(t) at Steady-State Conditions</measure>
    <time_frame>Measured at Week 28 before the start of the SC infusion, 10 minutes before the end of the infusion, and at 2 h, 1, 2, 3, 4 and 7 days after the end of the infusion. Calculated and averaged.</time_frame>
    <description>The primary endpoint with respect to the PK investigations is the area under the curve AUC(t) (i.e., AUC from time 0 (start of the infusion) to the end of the nominal dosing period, standardised to 1 week) at PKSC2 at steady-state conditions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Annual Rate of All Infections of Any Kind or Seriousness.</measure>
    <time_frame>Up to 65 weeks</time_frame>
    <description>The annual rate of all infections of any kind or seriousness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-serious Infections</measure>
    <time_frame>Up to 65 weeks</time_frame>
    <description>Non-serious infections (total and by category).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of Total IgG and IgG Subclasses</measure>
    <time_frame>Measured at week 28</time_frame>
    <description>Cmax (Maximum Plasma Concentration) of total IgG and IgG Subclasses, where the mean value was calculated and reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of Total IgG and IgG Subclasses</measure>
    <time_frame>Measured at Week 28 for all patients, median value was calculated</time_frame>
    <description>Tmax (Time to Maximum Plasma Concentration) of total IgG and IgG Subclasses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Total IgG and IgG Subclasses</measure>
    <time_frame>Measured at Week 28</time_frame>
    <description>AUC (Area Under the Concentration-Time Curve) of total IgG and IgG Subclasses calculated for all patients and mean value was calculated and reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Levels of Serum IgG</measure>
    <time_frame>Measured once at Week 28, seven days after 28th infusion of octanorm</time_frame>
    <description>Trough levels of serum IgG, IgG1, IgG2, IgG3, IgG4 at PK 7 days after 28th infusion of octanorm measured for all patients and median value was calculated and reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IVIG to Octanorm DCF (Based on the Area Under the Concentration-time Curve [AUCτ])</measure>
    <time_frame>AUC Measured at Week 28</time_frame>
    <description>IVIG to Octanorm Dose Conversion Factor (based on the area under the concentration-time curve [AUCτ]) -- determined by least-squares regression Model which was without restriction of the intercept.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Primary Immune Deficiency Disorder</condition>
  <arm_group>
    <arm_group_label>Octanorm 16.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>octanorm 16.5%</intervention_name>
    <description>octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.</description>
    <arm_group_label>Octanorm 16.5%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age of at least 2 years up to and including 75 years.&#xD;
&#xD;
          2. Confirmed diagnosis of PI as defined by the ESID and PAGID and requiring&#xD;
             immunoglobulin replacement therapy due to hypogammaglobulinaemia or&#xD;
             agammaglobulinaemia. The exact type of PI should be recorded.&#xD;
&#xD;
          3. Patients with at least 6 infusions on regular treatment with any IVIG, there of a&#xD;
             minimum of the last 2 months on the same product prior to entering the study. Constant&#xD;
             IVIG dose between 200 and 800 mg/kg body weight (±20% of the mean dose for the last 6&#xD;
             infusions).&#xD;
&#xD;
          4. Availability of the IgG trough levels of 2 previous IVIG infusions before enrollment,&#xD;
             and maintenance of greater than or equal to 5.0 g/L in the trough levels of these 2&#xD;
             previous infusions.&#xD;
&#xD;
          5. Negative result on a pregnancy test (HCG-based assay in urine) for women of&#xD;
             childbearing potential and use of a reliable method of contraception for the duration&#xD;
             of the study.&#xD;
&#xD;
          6. For adult patients: freely given written informed consent. For minor patients: freely&#xD;
             given written informed consent from parents/legal guardians and written informed&#xD;
             assent from the child/adolescent in accordance with the applicable regulatory&#xD;
             requirements.&#xD;
&#xD;
          7. Willingness to comply with all aspects of the protocol, including blood sampling, for&#xD;
             the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute infection requiring intravenous antibiotic treatment within 2 weeks prior to and&#xD;
             during the screening period.&#xD;
&#xD;
          2. Known history of adverse reactions to IgA in other products.&#xD;
&#xD;
          3. Patients with body mass index ≥40 kg/m2.&#xD;
&#xD;
          4. Exposure to blood or any blood product or plasma derivatives, other than IVIG&#xD;
             treatment for PID, within the past 3 months prior to the first infusion of octanorm.&#xD;
&#xD;
          5. Ongoing history of hypersensitivity or persistent reactions to blood or plasma derived&#xD;
             products, or any component of the investigational product (such as Polysorbate 80).&#xD;
&#xD;
          6. Requirement of any routine premedication for IgG administration.&#xD;
&#xD;
          7. History of malignancies of lymphoid cells and immunodeficiency with lymphoma.&#xD;
&#xD;
          8. Severe liver function impairment (ALAT 3 times above upper limit of normal).&#xD;
&#xD;
          9. Known protein-losing enteropathies or proteinuria.&#xD;
&#xD;
         10. Presence of renal function impairment (creatinine greater than 120 uM/L), or&#xD;
             creatinine greater than 1.35 mg/dL), or predisposition for acute renal failure (e.g.,&#xD;
             any degree of pre-existing renal insufficiency or routine treatment with known&#xD;
             nephritic drugs).&#xD;
&#xD;
         11. Treatment with oral or parenteral steroids for greater than or equal to 30 days or&#xD;
             when given intermittently or as bolus at daily doses greater than or equal to 0.15&#xD;
             mg/kg.&#xD;
&#xD;
         12. Treatment with immunosuppressive or immunomodulatory drugs.&#xD;
&#xD;
         13. Live viral vaccination (such as measles, rubella, mumps and varicella) within the last&#xD;
             2 months prior to first infusion of octanorm.&#xD;
&#xD;
         14. Treatment with any investigational medicinal product within 3 months prior to first&#xD;
             infusion of octanorm.&#xD;
&#xD;
         15. Presence of any condition, that is likely to interfere with the evaluation of study&#xD;
             medication or satisfactory conduct of the trial.&#xD;
&#xD;
         16. Known or suspected to abuse alcohol, drugs, psychotropic agents or other chemicals&#xD;
             within the past 12 months prior to first infusion of octanorm.&#xD;
&#xD;
         17. Known or suspected HIV, HCV, or HBV infection.&#xD;
&#xD;
         18. Pregnant or nursing women.&#xD;
&#xD;
         19. Planned pregnancy during the course of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Frenzel</last_name>
    <role>Study Director</role>
    <affiliation>International Medical Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Frisco</city>
        <state>Texas</state>
        <zip>75034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 2V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Montreal</city>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Brno</city>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Pilsen</city>
        <zip>304 60</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Prague</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-274</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>30-663</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-024</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197101</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620149</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Košice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Octapharma Research Site</name>
      <address>
        <city>Martin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 21, 2013</study_first_submitted>
  <study_first_submitted_qc>June 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2013</study_first_posted>
  <results_first_submitted>March 4, 2021</results_first_submitted>
  <results_first_submitted_qc>July 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2021</results_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PID</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Immunodeficiency Diseases</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 16, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT01888484/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT01888484/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Children ≥2 Years &lt;6 Years</title>
          <description>Children ≥2 Years &lt;6 Years</description>
        </group>
        <group group_id="P2">
          <title>Children Aged ≥6 to &lt;12 Years</title>
          <description>Children Aged ≥6 to &lt;12 years</description>
        </group>
        <group group_id="P3">
          <title>Adolescents ≥12 Years &lt;17 Years</title>
          <description>Adolescents ≥12 Years &lt;17 Years</description>
        </group>
        <group group_id="P4">
          <title>Adults ≥17 Years ≤75 Years</title>
          <description>Adults ≥17 Years ≤75 Years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Patients</title>
          <description>All patients.&#xD;
The data are reported as the overall population as it was not the intent of the protocol to report analysis by age group</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.81" spread="21.911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of SBI Per Person-year</title>
        <description>The primary efficacy outcome is the rate of SBI (Serious bacterial infections - defined as bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess) per person-year on treatment.</description>
        <time_frame>Every 4 weeks until the final evaluation at week 65.</time_frame>
        <population>The data are reported as the overall population as it was not the intent of the protocol to report analysis by age group</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of SBI Per Person-year</title>
          <description>The primary efficacy outcome is the rate of SBI (Serious bacterial infections - defined as bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess) per person-year on treatment.</description>
          <population>The data are reported as the overall population as it was not the intent of the protocol to report analysis by age group</population>
          <units>SBIs per person year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC(t) at Steady-State Conditions</title>
        <description>The primary endpoint with respect to the PK investigations is the area under the curve AUC(t) (i.e., AUC from time 0 (start of the infusion) to the end of the nominal dosing period, standardised to 1 week) at PKSC2 at steady-state conditions.</description>
        <time_frame>Measured at Week 28 before the start of the SC infusion, 10 minutes before the end of the infusion, and at 2 h, 1, 2, 3, 4 and 7 days after the end of the infusion. Calculated and averaged.</time_frame>
        <population>In several cases, AUCτ could not be calculated due to very flat time-concentration profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Total Patients</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(t) at Steady-State Conditions</title>
          <description>The primary endpoint with respect to the PK investigations is the area under the curve AUC(t) (i.e., AUC from time 0 (start of the infusion) to the end of the nominal dosing period, standardised to 1 week) at PKSC2 at steady-state conditions.</description>
          <population>In several cases, AUCτ could not be calculated due to very flat time-concentration profiles.</population>
          <units>h*g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2232.61" spread="585.842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Annual Rate of All Infections of Any Kind or Seriousness.</title>
        <description>The annual rate of all infections of any kind or seriousness.</description>
        <time_frame>Up to 65 weeks</time_frame>
        <population>The data are reported as the overall population as it was not the intent of the protocol to report analysis by age group</population>
        <group_list>
          <group group_id="O1">
            <title>Total Patients</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>The Annual Rate of All Infections of Any Kind or Seriousness.</title>
          <description>The annual rate of all infections of any kind or seriousness.</description>
          <population>The data are reported as the overall population as it was not the intent of the protocol to report analysis by age group</population>
          <units>infections per person-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-serious Infections</title>
        <description>Non-serious infections (total and by category).</description>
        <time_frame>Up to 65 weeks</time_frame>
        <population>The data are reported as the overall population as it was not the intent of the protocol to report analysis by age group</population>
        <group_list>
          <group group_id="O1">
            <title>Total Patients</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Non-serious Infections</title>
          <description>Non-serious infections (total and by category).</description>
          <population>The data are reported as the overall population as it was not the intent of the protocol to report analysis by age group</population>
          <units>infections</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ear infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections of the GI tract</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections of the genitourinary tract</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper respiratory tract infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower respiratory tract infections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections of the skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections not (elsewhere) classified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of Total IgG and IgG Subclasses</title>
        <description>Cmax (Maximum Plasma Concentration) of total IgG and IgG Subclasses, where the mean value was calculated and reported</description>
        <time_frame>Measured at week 28</time_frame>
        <population>The data are reported as the overall population as it was not the intent of the protocol to report analysis by age group. Data not available for all patients.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Total IgG and IgG Subclasses</title>
          <description>Cmax (Maximum Plasma Concentration) of total IgG and IgG Subclasses, where the mean value was calculated and reported</description>
          <population>The data are reported as the overall population as it was not the intent of the protocol to report analysis by age group. Data not available for all patients.</population>
          <units>g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgG Total Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.47" spread="3.655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG1 Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.56" spread="1.858"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG2 Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.88" spread="1.532"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG3 Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG4 Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.567"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of Total IgG and IgG Subclasses</title>
        <description>Tmax (Time to Maximum Plasma Concentration) of total IgG and IgG Subclasses</description>
        <time_frame>Measured at Week 28 for all patients, median value was calculated</time_frame>
        <population>The data are reported as the overall population as it was not the intent of the protocol to report analysis by age group. Data not available for all patients.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of Total IgG and IgG Subclasses</title>
          <description>Tmax (Time to Maximum Plasma Concentration) of total IgG and IgG Subclasses</description>
          <population>The data are reported as the overall population as it was not the intent of the protocol to report analysis by age group. Data not available for all patients.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tmax Total IgG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.62" lower_limit="0.8" upper_limit="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax IgG1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.50" lower_limit="1.5" upper_limit="167.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax IgG2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.20" lower_limit="0.5" upper_limit="167.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax IgG3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.62" lower_limit="1.8" upper_limit="98.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tmax IgG4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.50" lower_limit="0.6" upper_limit="167.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC of Total IgG and IgG Subclasses</title>
        <description>AUC (Area Under the Concentration-Time Curve) of total IgG and IgG Subclasses calculated for all patients and mean value was calculated and reported</description>
        <time_frame>Measured at Week 28</time_frame>
        <population>The data are reported as the overall population as it was not the intent of the protocol to report analysis by age group. Data not available for all patients.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>AUC of Total IgG and IgG Subclasses</title>
          <description>AUC (Area Under the Concentration-Time Curve) of total IgG and IgG Subclasses calculated for all patients and mean value was calculated and reported</description>
          <population>The data are reported as the overall population as it was not the intent of the protocol to report analysis by age group. Data not available for all patients.</population>
          <units>hr*g/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IgG Total AUC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2232.61" spread="585.842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG1 AUC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1424.69" spread="298.776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG2 AUC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="659.57" spread="262.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG3 AUC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.65" spread="18.455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG4 AUC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.40" spread="102.578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Levels of Serum IgG</title>
        <description>Trough levels of serum IgG, IgG1, IgG2, IgG3, IgG4 at PK 7 days after 28th infusion of octanorm measured for all patients and median value was calculated and reported</description>
        <time_frame>Measured once at Week 28, seven days after 28th infusion of octanorm</time_frame>
        <population>The data are reported as the overall population as it was not the intent of the protocol to report analysis by age group. Data not available for all patients.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Levels of Serum IgG</title>
          <description>Trough levels of serum IgG, IgG1, IgG2, IgG3, IgG4 at PK 7 days after 28th infusion of octanorm measured for all patients and median value was calculated and reported</description>
          <population>The data are reported as the overall population as it was not the intent of the protocol to report analysis by age group. Data not available for all patients.</population>
          <units>g/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total IgG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.85" lower_limit="10.00" upper_limit="13.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.51" lower_limit="6.58" upper_limit="9.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" lower_limit="2.69" upper_limit="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" lower_limit="0.20" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IgG4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="0.11" upper_limit="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IVIG to Octanorm DCF (Based on the Area Under the Concentration-time Curve [AUCτ])</title>
        <description>IVIG to Octanorm Dose Conversion Factor (based on the area under the concentration-time curve [AUCτ]) -- determined by least-squares regression Model which was without restriction of the intercept.</description>
        <time_frame>AUC Measured at Week 28</time_frame>
        <population>The data are reported as the overall population as it was not the intent of the protocol to report analysis by age group. Data not available for all patients.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients</description>
          </group>
        </group_list>
        <measure>
          <title>IVIG to Octanorm DCF (Based on the Area Under the Concentration-time Curve [AUCτ])</title>
          <description>IVIG to Octanorm Dose Conversion Factor (based on the area under the concentration-time curve [AUCτ]) -- determined by least-squares regression Model which was without restriction of the intercept.</description>
          <population>The data are reported as the overall population as it was not the intent of the protocol to report analysis by age group. Data not available for all patients.</population>
          <units>unitless</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.278" spread="0.9401"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For the duration of the 65 week treatment period starting with the first infusion of octanorm.</time_frame>
      <desc>The data are reported as the overall population as it was not the intent of the protocol to report analysis by age group</desc>
      <group_list>
        <group group_id="E1">
          <title>All Patients</title>
          <description>All patients</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Acute odontogenic jaw osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pneumocystitis jiroveci infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Asperger's syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="37" subjects_affected="17" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Rhinovirus infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="15" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="33" subjects_affected="21" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="6" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Any infusion site reaction</sub_title>
                <counts group_id="E1" events="994" subjects_affected="55" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mikaela Raymond</name_or_title>
      <organization>Clinical Research Management Group</organization>
      <phone>866-337-1868</phone>
      <email>ctgov@cllinicalresearchmgt.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

